CASE CCC IN THE NEWS
Cancer Research and Other Medical Funding is Hurt by Congress's Budget Games
The Plain Dealer - Sept 16, 2014
Cancer survivors, their relatives, physicians and supporters will fan across Capitol Hill today to urge Congress to do something it has no intention of doing right now: Providing substantially more money for cancer research, including clinical trials of promising drugs and treatments. Congress instead plans to pass a temporary measure to take effect Oct. 1 with no or minimal spending increases. Congress may consider spending hikes in December, but only once its political makeup for 2015 is clear.
This does not mean that Congress will or won't eventually cut or raise the amount of money it already provides for medical research at centers like Case Western Reserve University, University Hospitals and the Cleveland Clinic. And the timing of Congress's budget dance is only slightly coincidental with the fact that Dr. Stanton Gerson, director of the Case Comprehensive Cancer Center and the Seidman Cancer Center, came to Washington to participate in Cancer Lobby Day, sponsored by the American Cancer Society's advocacy group, the Cancer Action Network...
Baldness and Prostate Cancer: Latest study offers more evidence to link the two conditions
The Plain Dealer- Sept 16, 2014
The latest study to suggest a link between male pattern baldness and prostate cancer shows men with moderate male pattern baldness by age 45 at increased risk of developing aggressive prostate cancer later in life, compared to men who were not bald. The study, paid for by the National Cancer Institute, was published Monday in the Journal of Clinical Oncology, a publication of the American Society of Clinical Oncology. According to the researchers who conducted the analysis, it is the largest of its kind to date, and one of a few to differentiate between aggressive and non-aggressive prostate cancers...But a Cleveland Clinic urologist who was not involved in the research says it wouldn't hurt for men who have noticeable male pattern baldness to be screened for prostate cancer. One of the criticisms often leveled at prostate-specific antigen, or PSA, blood tests is that they aren't focused on high-risk populations, said Dr. Eric Klein, chairman of the Clinic's Glickman Urological & Kidney Institute. "This study identifies what I consider a high-risk population," he said. "[The men have] an individual patient characteristic that predisposes them to screening."
Phase I Clinical Trials Test New Therapies for Kids' Cancers
Contemporary Pediatrics - Sept. 1, 2014
Robin Norris, MD, a pediatric oncologist and assistant professor of pediatrics, Case Western Reserve University, Cleveland, Ohio, agrees that access to drugs is a barrier to pediatric cancer research. "I think our biggest limitation is actually the number of trials and the number of agents that we, as pediatric oncologists, have access to. There are a lot of phase I studies that are geared toward the adult population but a lot of those agents are not available to children under the age of 18," she says.
RESEARCH HIGHLIGHTS/MEMBER NEWS
Dowlati Helps Lead Study on Potential Treatment Approaches that Could Extend Life of Mesothelioma Patients
A common Asian spice and cancer-hampering molecules show promise in slowing the progression of mesothelioma, a cancer of the lung's lining often linked to asbestos. Scientists from Case Western Reserve University and the Georg-Speyer-Haus in Frankfurt, Germany, demonstrate that application of curcumin, a derivative of the spice turmeric, and cancer-inhibiting peptides increase levels of a protein inhibitor known to combat the progression of this cancer. Their findings appeared in the August 14 online edition Clinical Cancer Research; the print version of the article will appear October 1.
"Mesothelioma is a disease that continues to have a significant burden worldwide, and the treatment option is really suboptimal. We must find better ways to treat it," said senior author Afshin Dowlati, MD, Professor of Medicine – Hematology/Oncology, Case Western Reserve University School of Medicine, and member of the Case Comprehensive Cancer Center. "We now understand the mechanisms that drive cell proliferation and growth in malignant mesothelioma."
Radiology's Mark Griswold Earns Medical School's Top Honor
Last week, Mark Griswold, PhD, Professor of Radiology, was awarded the CWRU School of Medicine Medal for Excellence in Health Science Innovation, one of its highest honors, to recognize his extraordinary dedication and accomplishments.
Michael Vogelbaum Appointed to NCI Brain Malignancy Steering Committee
Michael A. Vogelbaum MD, PhD has been appointed to the Brain Malignancy Steering Committee of the National Cancer Institute. This committee functions to review and prioritize adult and pediatric phase II and phase III clinical trials submitted for NCI funding. Dr. Vogelbaum also currently serves as the Co-Chair of the Brain Site Committee and Chair of the Neurosurgery Subcommittee at NRG Oncology, one of four adult clinical trials groups in the NCI's National Clinical Trials Network (NCTN).
MARK YOUR CALENDARS
Fall 2014 Case CCC Clinical Research Retreat
The Case CCC will be holding a Clinical Research Retreat on October 7 in the Wolstein Research Building. A reception will be held from 5-5:30 pm, followed by presentations from 5:30-7 pm.
The agenda will focus on the theme of Immunotherapy:
James Finke, PhD: Strategies to Reduce Immune Suppression as a Means to Improve Immunotherapy: A laboratory perspective
Joseph Baar, MD: Recent Advances in the Immunotherapy of Cancer
Shaveta Vinayak, MD: Tumor Infiltrating Lymphocytes Predict for Response to Therapy in Triple-negative Breast Cancer
Mitchell Machtay, MD: National Clinical Trials Network/Cooperative Groups (NCTN) Update
Pre-registration is required. Please contact Dr. Smitha Krishnamurthi (smitha.krishnamurthi@UHhospitals.org) with any questions. We hope everyone interested in clinical trials can attend!
2014 Adolescent and Young Adult Cancers Symposium
This first Adolescent and Young Adult (AYA) cancer conference hosted by the Case Comprehensive Cancer Center is being held October 30-31 at the Iris S. & Bert L. Wolstein Research Building. This collaborative symposium is organized by the Angie Fowler Adolescent & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children's Hospital, UH Seidman Cancer Center, Case Comprehensive Cancer Center, and the Oregon Health & Science University Knight Cancer Institute. The focus of this two-day symposium is on advancement of AYA-related cancer research, including exploration of scientific, clinical and psychological considerations in adolescent and young adult cancer patients.
The symposium features speakers from leading academic institutions and non-profit organizations who are at the forefront of AYA research and advocacy, including Heidi Adams, CEO of Critical Mass, and Simon Davies, CEO of Teen Cancer America. We are excited to feature two key speakers from University Hospitals Case Medical Center, Dr. Henry Koon, Disease Team Leader of Melanoma and Dr. Cheryl Kingsberg, Division Chief Ob/GYN Behavioral Medicine, CWRU Obstetrics and Gynecology, University Hospitals MacDonald Women's Hospital.
The symposium also features a keynote address by Clifton Leaf, Deputy Managing Editor, "Fortune Magazine," and author, "The Truth in Small Doses: Why We're Losing the War on Cancer And How to Win It." Mr. Leaf is a cancer survivor and a national advocate for change to the way the global cancer fight is funded and pursued, pushing for ways to speed up progress against the disease. Mr. Leaf has presented testimony to the President's Cancer Panel three times, given a plenary address at the annual meeting of the American Association for Cancer Research, and delivered Grand Rounds at the National Cancer Institute, the only journalist to be given that honor.
We hope that you will join us this year for our first AYA cancer conference, and we hope that we can help you connect to an international community of researchers and advocates for the AYA cancer community. Register today! Continuing Medical Education credits are available.
5th Annual DeGregorio Foundation Award for Cancers of the Esophagus and Stomach
The DeGregorio Family Foundation for Gastric and Esophageal Cancer is pleased to announce the 5th annual funding opportunity for gastroesophageal malignancies. The Foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis, and treatment of upper gastrointestinal malignancies. The Foundation supports high quality, innovative, and transformative translational and bench research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment. Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies, as well as epidemiologic studies may also be supported.
Deadline: November 3
Support of Multi-investigator Initiatives in the Case CCC
The Case CCC will provide two modes of support to new research teams that plan to submit large multi-investigator grant applications (usually non-R support mechanisms).
- Administrative support and funding for travel are available to encourage team member meetings and meetings with external advisors.
- Pilot project funding for research teams with an established track record of collaborative research is available to support key research initiatives that are necessary to generate competitive multi-investigator proposals.
Requests are competitive. The research team must demonstrate the active engagement of members, clearly articulate the significance and innovation of the project, and provide a roadmap for acquisition of external funding.
Advocacy and support of the specific program leadersinteracting with the team is required. Discussion with Ruth Keri, PhD, Associate Director for Basic Research, is strongly encouraged before developing an application.
PREVIOUSLY ANNOUNCED OPPORTUNITIES
AACR Award for Lifetime Achievement in Cancer Research
American Skin Association Research Grants
Support of Multi-investigator Initiatives in the Case CCC
NIH BULLETIN – Notices and Funding Opportunities
Notice of Pre-application Webinar for RFA-CA-14-018 "Pediatric Preclinical Testing Consortium: Research Programs (U01)" and RFA-CA-14-019 "Pediatric Preclinical Testing Consortium: Coordinating Center (U01)" (NOT-CA-14-047)
Erratum to RFA-CA-14-012 ""Cancer Intervention and Surveillance Modeling Network (CISNET) (U01)"(NOT-CA-14-056)
Administrative Supplements for U.S. – Brazil Biomedical Collaborative Research (PA-14-328)
Revisions for Early-Stage Development of Informatics Technology (R01)(PAR-12-286)
Early-Stage Development of Informatics Technology (U01)(PAR-12-288)
Revisions for Early-Stage Development of Informatics Technology (U01)(PAR-12-289)
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)(PAR-13-036)
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.